The first case details the response to breast cancer therapy in a woman with ER+/PR+ metastatic disease treated concomitantly with exemestane, an AI, and octreotide for her acromegaly; the subject’s breast cancer progressed when she was nonadherent with octreotide therapy [19]. This evidence concerns the gene ESR1 and breast carcinoma.